Based on the analysis of Pharming Group's profitability, liquidity, and operating efficiency, Pharming Group NV is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. At this time, Pharming Group's Cash is relatively stable compared to the past year. As of 03/21/2025, Non Current Assets Total is likely to grow to about 176.9 M, though Current Deferred Revenue is likely to grow to (61.4 K). Key indicators impacting Pharming Group's financial strength include:
The essential information of the day-to-day investment outlook for Pharming Group includes many different criteria found on its balance sheet. An individual investor should monitor Pharming Group's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Pharming Group.
Pharming Group competes with Genenta Science, Opthea, Mineralys Therapeutics,, Anebulo Pharmaceuticals, and Janux Therapeutics. Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. Pharming Group N.V. is headquartered in Leiden, the Netherlands. Pharming Group operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 277 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what Pharming Group's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Pharming Group's current stock value. Our valuation model uses many indicators to compare Pharming Group value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Pharming Group competition to find correlations between indicators driving Pharming Group's intrinsic value. More Info.
Pharming Group NV is considered to be number one stock in return on equity category among its peers. It is regarded second in return on asset category among its peers . At this time, Pharming Group's Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Pharming Group by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Pharming Group NV Systematic Risk
Pharming Group's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Pharming Group volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Pharming Group NV correlated with the market. If Beta is less than 0 Pharming Group generally moves in the opposite direction as compared to the market. If Pharming Group Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Pharming Group NV is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Pharming Group is generally in the same direction as the market. If Beta > 1 Pharming Group moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Pharming Group Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Pharming Group's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Pharming Group growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of Pharming Group help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Pharming Group NV. We use our internally-developed statistical techniques to arrive at the intrinsic value of Pharming Group NV based on widely used predictive technical indicators. In general, we focus on analyzing Pharming Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Pharming Group's daily price indicators and compare them against related drivers.
When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.